EverSource Wealth Advisors »

Inhibikase Therapeutics shares owned by EverSource Wealth Advisors

Quarter-by-quarter ownership of Inhibikase Therapeutics (IKT) shares owned by EverSource Wealth Advisors from 13F filings

Historical chart of EverSource Wealth Advisors investment in Inhibikase Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Inhibikase Therapeutics held by EverSource Wealth Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Inhibikase Therapeutics by EverSource Wealth Advisors

Quarter filed Position value Share count Share price at filing
2025-12-31 $8 4 2.00

More positions owned by EverSource Wealth Advisors

Vanguard Growth Etf Etf (VUG)
Vanguard Value Etf Etf (VTV)
Vanguard Ftse Developed Markets Etf Etf (VEA)
iShares Gold Trust ETF Etf (IAU)
State Street Spdr Bloomberg 1-3 Month T-bill Etf Etf (BIL)
Apple Stock (AAPL)
Praxis Impact Large Cap Growth Etf Etf (PRXG)
Nvidia Corporation Stock (NVDA)
Praxis Impact Large Cap Value Etf Etf (PRXV)
Apollo Global Mgmt Stock (APO)
Tesla Stock (TSLA)
Microsoft Corp Stock (MSFT)
Alphabet Inc Cap Stk Cl A Stock (GOOGL)
Fidelity Wise Origin Bitcoin Fund Etf (FBTC)
Vanguard 0-3 Month Treasury Bill Etf Etf (VBIL)

View all positions for EverSource Wealth Advisors

Top funds holding Inhibikase Therapeutics

Sands Capital Ventures
Soleus Capital Management
Fairmount Funds Management
ADAR1 Capital Management
Siren
Perceptive Advisors
Commodore Capital
Vanguard Group
Nantahala Capital Management
Saturn V Capital Management
BlackRock
Blackstone Group
Stonepine Capital Management
Integral Health Asset Management
Ameriprise Financial

View all funds holding Inhibikase Therapeutics